| Pack Size | Single Vial, 10-Pack |
|---|
Glow Blend is a research-supply formulation pairing three of the most-extensively-characterised peptides in skin-and-tissue-repair research at fixed proportions in a single lyophilized vial. The peptide loadings are 50 mg of GHK-Cu, plus 10 mg each of the two tissue-repair peptides BPC-157 and TB-500, for 70 mg of total peptide content. The blend is offered for combined-compound benchwork that engages three non-overlapping mechanism niches — Cu(II)-carrier ECM remodelling, VEGFR2-Akt-eNOS vascular signalling, and parent-Thymosin-β-4 actin-cytoskeleton dynamics. Every Ronin batch is independently verified by Janoshik Analytical using HPLC for purity quantification of each component compound and mass spectrometry for identity confirmation. Supplied as a lyophilized blue-tinted powder in a sealed glass vial. For laboratory research use only — not for human or veterinary use.
Description
Glow Blend is a fixed-ratio research-supply formulation that combines three peptides into a single lyophilized vial. The vial holds fifty milligrams of GHK-Cu, plus ten milligrams each of BPC-157 and TB-500. Total peptide content sums to seventy milligrams. Each component compound is also available from Ronin Peptides as a standalone single-compound vial; the blend format pairs them at convenient working concentrations for combined-compound experiments.
The blend's lyophilized form takes a characteristic blue-to-blue-violet tint owing to the GHK-Cu Cu(II) chromophore — the copper-2 ion bound at the histidine-imidazole chelation pocket of the GHK tripeptide absorbs visible light in the orange-red wavelength range and transmits the complementary blue. Reconstituted aqueous solutions retain the visible blue tint at typical research working concentrations, which serves as a useful visual indicator that the GHK-Cu complex's copper-2 binding remains intact. Loss of colour during storage signals copper-ligand dissociation and corresponds to a drop in the active GHK-Cu concentration; the BPC-157 and TB-500 components do not contribute to the visible-spectrum chromophore.
The compound is supplied as a sealed amber-glass vial under inert gas. Reconstitution with bacteriostatic water is required before any of the three component peptides can be drawn into an insulin syringe. Reconstitution math is per-component: a single 70 mg vial reconstituted with 2 mL of bacteriostatic water yields 25 mg/mL of GHK-Cu, 5 mg/mL of BPC-157, and 5 mg/mL of TB-500 simultaneously — the three peptides share the same diluent volume but contribute distinct working concentrations corresponding to their respective vial loadings. Reconstitution mechanics are covered in the Reconstitution accordion below.
The three component peptides occupy non-overlapping mechanism niches across the skin-and-tissue-repair research landscape. GHK-Cu has been investigated for ECM remodelling, fibroblast and keratinocyte cellular pathway modulation, antioxidant chemistry, and gene-expression regulation, with the literature anchored by half a century of work since the original Pickart-laboratory characterisation. BPC-157 has been investigated for vascular and angiogenic signalling through VEGFR2 receptor activation and the downstream Akt-eNOS branch, alongside gastric-protection and growth-hormone-receptor-upregulation findings (PMID 27847966, PMID 21030672, PMID 34267654). TB-500's parent Thymosin β-4 has been characterised for actin-cytoskeleton dynamics, cell migration, cardiac progenitor mobilisation, and corneal wound-healing in foundational and contemporary research (PMID 11579089, PMID 15565145, PMID 11950239).
The blend's components have been investigated in combination protocols across dermal-research, tissue-repair, and combined-mechanism studies. Recent reviews (PMID 38879894, PMID 38980576, PMID 41966639) compile contemporary framings.
No regulatory authority — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has cleared any of the three component compounds, or the blend formulation, as a drug for human or veterinary use. GHK-Cu carries cosmetic-ingredient approval under the INCI name Copper Tripeptide-1 in multiple jurisdictions; cosmetic approval is regulatorily distinct from drug approval. None of the three compounds are listed as scheduled controlled substances under the international drug-control conventions or under the major national scheduling systems. Ronin Peptides ships the blend exclusively as a research-grade reagent for benchwork. Dosing protocols, treatment regimens, and administration instructions are out of scope and not provided in any form.
Mechanism in research literature
The blend's three components engage three molecular niches that do not overlap at the receptor or signalling-pathway level. Investigators studying combined-compound protocols often cite this non-overlap as the rationale for blend formats — each compound contributes activity at a distinct molecular target without competing for the same receptor or downstream effector.
GHK-Cu's mechanism centres on Cu(II) carrier function and broad gene-regulatory effects. The Gly-His-Lys tripeptide chelates a single copper-2 ion at a square-planar coordination pocket built from the histidine imidazole nitrogen and adjacent backbone amides. A 2001 Biochimica et Biophysica Acta paper anchored the foundational chelation chemistry of the tripeptide-copper system (PMID 11325542). A 2018 review in the International Journal of Molecular Sciences compiled transcriptome-profiling data showing thousands of human genes flagged as differentially expressed under GHK-Cu exposure across multiple cell-type studies (PMID 29986520). The 2015 Pickart-laboratory review compiled the multiple cellular pathways modulated in skin-regeneration model systems, including collagen and elastin synthesis stimulation, fibroblast migration, and matrix-deposition findings (PMID 26236730).
BPC-157's mechanism centres on VEGFR2 receptor activation and downstream vascular signalling. A 2017 paper in the Journal of Molecular Medicine documented receptor activation and upregulation in vascular endothelium (PMID 27847966); the Akt-eNOS branch downstream of VEGFR2 has been characterised across multiple research groups. A 2011 paper in the Journal of Applied Physiology documented growth-hormone-receptor expression upregulation in tendon fibroblasts following BPC-157 exposure, alongside enhanced cell migration and survival in tissue-repair models (PMID 21030672). The 2021 Frontiers in Pharmacology review compiled the wound-healing literature across tendon, ligament, muscle, bone, peripheral-nerve, and vascular models (PMID 34267654).
TB-500's mechanism rests on the parent Thymosin β-4's role as the principal G-actin-sequestering peptide in mammalian cells. The seven-residue supply-form fragment retains the binding-active stretch of the parent. A 2001 Journal of Biological Chemistry paper characterised the ternary complex among profilin, Thymosin β-4, and actin (PMID 11579089). A 2004 Nature paper documented that parent Thymosin β-4 activates integrin-linked kinase and supported cardiac cell migration, survival, and post-infarct repair in mouse models (PMID 15565145). Corneal-research applications have been characterised since a 2002 Experimental Eye Research paper (PMID 11950239) and through recent 2025 engineered-fragment work.
The three mechanism niches converge at the tissue-and-cellular-response level — the cytoskeletal, vascular, and gene-regulatory effects collectively contribute to the broader tissue-repair and skin-research framings under which all three compounds appear. The 2016 Vitamins and Hormones review compiled the dermal-healing literature on Thymosin β-4 alongside related research (PMID 27450738). Recent 2024 and 2026 reviews have placed the blend's components into broader peptide-therapy framings (PMID 38879894, PMID 38980576, PMID 41966639, PMID 41490200).
Studied properties
Skin-and-dermal research forms the largest application bracket for combined-compound research with the blend's components. GHK-Cu's dermal-matrix work (PMID 26236730, PMID 29986520), BPC-157's wound-healing literature (PMID 34267654), and TB-500's parent dermal-healing review (PMID 27450738) collectively provide three complementary foundations.
Tissue-repair research more broadly has produced cross-compound findings, with multiple groups having investigated, characterised, and documented the three molecules across overlapping injury models. BPC-157's tendon-repair work (PMID 21030672) connects to TB-500's cardiac and corneal repair findings (PMID 15565145, PMID 11950239) and to GHK-Cu's regenerative-research framework — the cross-stream pattern motivating combined investigations.
Combined-mechanism research typically positions the three compounds as engaging non-overlapping pathways rather than as synergistic compounds — a research-context distinction that matters for experimental interpretation. Multiple groups have observed and characterised this independence across in vitro and animal-model studies. GHK-Cu's Cu(II)-carrier mechanism does not engage the VEGFR2 receptor through which BPC-157 acts; BPC-157's vascular-signalling pathway does not engage the actin-cytoskeleton effects through which the parent Thymosin β-4 acts. The three compounds can be examined separately or in combination without concern about competitive receptor binding.
Antioxidant research forms a fourth stream specific to GHK-Cu. The compound has been characterised through Michael-addition aldehyde-quenching and superoxide-dismutase-mimetic activity in the copper-bound complex; the 2024 Redox Biology paper extended findings into murine lung-inflammation and fibrosis attenuation (PMID 38879894). The other two components do not engage the same direct-antioxidant framework.
Translation to human clinical application has been narrower than the breadth of the preclinical literature for any of the three components. Recent reviews (PMID 38980576, PMID 41966639, PMID 41490200) compile contemporary framings; investigators should attend to the regulatory context, since none of the three components are approved as drugs in any major jurisdiction.
Compound specifications
The blend contains three distinct compounds at the proportions listed below. Per-compound specifications follow.
| Specification | GHK-Cu | BPC-157 | TB-500 |
|---|---|---|---|
| Content per vial | 50 mg | 10 mg | 10 mg |
| Sequence | Gly-His-Lys + Cu(II) | GEPPPGKPADDAGLV | LKKTETQ |
| Length | 3 amino acids | 15 amino acids | 7 amino acids |
| Molecular formula | C14H23CuN6O4 | C62H98N16O22 | (7-residue acetate) |
| Molecular weight | ~403.93 g/mol | 1419.55 g/mol | ~889 g/mol |
| CAS number | 89030-95-5 | 137525-51-0 | (fragment) |
| PubChem CID | 11954184 | 9941957 | — |
| Mechanism niche | Cu(II) carrier; ECM remodelling | VEGFR2-Akt-eNOS pathway | Parent Thymosin β-4 G-actin sequestration |
Total peptide loading per vial: 70 mg. Form: lyophilized blue-tinted powder (Cu(II) chromophore from GHK-Cu component). Solubility: bacteriostatic water; sterile water for injection. Storage: sealed amber-glass vial under inert gas. Purity: ≥99% per component by HPLC, verified per batch by Janoshik Analytical against the three expected molecular masses.
One specification note worth flagging: the COA returned for the blend reports the analytical results for each of the three component compounds separately. Investigators integrating the blend into mass-spec-coupled protocols should expect three distinct mass-spec peaks corresponding to the three components, plus characterisation of the salt and counterion forms returned in the per-batch documentation. The molecular-weight values quoted above correspond to the most commonly reported supply forms; per-batch COA documentation may differ slightly depending on salt counterion conventions.
Storage and handling
Unopened lyophilized vials hold up well under dry ambient storage; usable activity persists for several weeks even without refrigeration. The recommended container is the unopened original vial — keep the seal intact until reconstitution. Refrigeration at 2–8 °C is appropriate once the working timeline extends past a month. A standard freezer at −20 °C handles archival storage; ultra-low storage at −80 °C is rarely needed for typical bench-research timescales.
Keep vials shielded from light, ideally in their original outer packaging. The Cu(II) chromophore is photostable in lyophilized form, but reconstituted aqueous solutions show somewhat accelerated degradation under direct UV exposure compared with the dry vial. Repeated temperature cycling accelerates degradation noticeably more than steady storage at any single temperature inside the recommended bands — minimise transitions between cold and ambient.
After reconstitution, refrigerate the solution at 2–8 °C without delay. The typical working window is four to six weeks at fridge temperature — the same window as each component compound individually. Past that window, peptide concentration drifts downward through chemical degradation pathways. The bacteriostatic water's 0.9% benzyl alcohol holds back bacterial contamination but does not arrest hydrolysis, oxidation, copper-ligand-dissociation, and aggregation processes. The three components may degrade at slightly different rates; the limiting component is typically GHK-Cu, where loss of the blue Cu(II) chromophore is a useful visual indicator of concentration drift. The BPC-157 and TB-500 components do not contribute to the colour; their status requires COA mass-spec confirmation.
When a research timeline extends past six weeks, common practice is splitting the reconstituted solution into single-use volumes and freezing them at −20 °C immediately. Ice-crystal formation during each freeze-thaw cycle inflicts mechanical damage on peptide chains, and pre-splitting eliminates the cumulative loss that comes from thawing one vial multiple times. Thaw individual aliquots overnight in a refrigerator — never at room temperature — and use them within a few days of thaw.
The reconstituted product should be visually transparent with a characteristic blue tint and no suspended particulate. Discard any vial showing turbidity, suspended particulate, yellowing, decolourisation, or visible precipitate. The diluent of choice is USP-grade bacteriostatic water containing 0.9% benzyl alcohol — see the bacteriostatic water product page for reconstitution-grade water.
Compare with related blends and individual compounds
| Format | Components | Total peptide | Format at Ronin |
|---|---|---|---|
| Glow Blend | GHK-Cu + BPC-157 + TB-500 | 70 mg total (50 + 10 + 10) | 70 mg blend vial |
| BPC-157 + TB-500 Blend | BPC-157 + TB-500 | 20 mg total (10 + 10) | 20 mg blend vial |
| KLOW Blend | GHK-Cu + BPC-157 + TB-500 + KPV | 80 mg total (50 + 10 + 10 + 10) | 80 mg blend vial |
| GHK-Cu standalone | GHK-Cu only | 50 mg per vial | 50 mg vial |
| BPC-157 standalone | BPC-157 only | 10 mg per vial | 10 mg vial |
| TB-500 standalone | TB-500 only | 10 mg per vial | 10 mg vial |
Glow Blend sits within Ronin's blend-format category alongside the BPC-157 + TB-500 combined blend and the four-component KLOW Blend. Choice of format depends on the research question. Investigators studying the GHK-Cu component specifically alongside the two tissue-repair compounds use Glow Blend; investigators focused exclusively on the tissue-repair pair use the smaller two-component blend; investigators who additionally want the KPV anti-inflammatory tripeptide use the four-component KLOW Blend. Each component compound is also available as a standalone single-compound vial for investigators who prefer to control individual concentrations independently.
Reconstitution and laboratory handling
Reconstituting the Glow Blend follows the same procedure as a single-compound vial, with one important difference: the resulting solution contains three peptides at three distinct concentrations corresponding to their per-vial loadings. A single 70 mg vial reconstituted with 2 mL of bacteriostatic water yields the following per-component working concentrations:
- GHK-Cu: 25 mg/mL (50 mg / 2 mL) = 25,000 mcg/mL
- BPC-157: 5 mg/mL (10 mg / 2 mL) = 5,000 mcg/mL
- TB-500: 5 mg/mL (10 mg / 2 mL) = 5,000 mcg/mL
Other diluent volumes scale linearly. A 5 mL reconstitution gives GHK-Cu at 10 mg/mL, BPC-157 at 2 mg/mL, and TB-500 at 2 mg/mL. A 10 mL reconstitution gives GHK-Cu at 5 mg/mL, BPC-157 at 1 mg/mL, and TB-500 at 1 mg/mL. Researchers planning experiments should choose the diluent volume based on which component's working concentration is the primary experimental anchor.
Reconstitution procedure:
- Bring both vials — peptide blend and bacteriostatic water — to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and denatures peptide at the air-water interface.
- Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
- Refrigerate at 2–8 °C the moment reconstitution completes.
A finished preparation should be visually transparent with a characteristic blue tint and no suspended particulate. The blue colour confirms intact Cu(II) chelation on the GHK-Cu component; loss of colour during storage signals copper-ligand dissociation. If the solution is hazy, contains visible material, or has decolourised, treat it as degraded and discard. Bench operators have documented and reported this colour-stability behaviour consistently across cell-culture and animal-model preparations.
For dose-volume calculations on insulin syringes, use the Ronin peptide reconstitution calculator. The calculator handles per-component concentration arithmetic for blend formats.
Per-component dose ranges in published preclinical research differ across the three compounds, with each component examined under distinct dosing protocols by independent research groups. GHK-Cu has been examined across cell-culture concentrations in the nanomolar to low-micromolar range and at micrograms-per-kilogram parenteral dosing in animal models. BPC-157 has been administered in animal models at 6 to 50 micrograms per kilogram across multiple routes. TB-500's parent Thymosin β-4 has been administered at micrograms-per-kilogram parenteral dosing in cardiac and corneal model systems. These figures are research-reference only — Ronin Peptides does not provide dosing recommendations or administration instructions for any non-laboratory purpose.
Frequently asked questions
What is Glow Blend?
Glow Blend is a research-supply formulation pairing three peptides. Each is at fixed proportion in a single lyophilized vial. The peptide loadings are 50 mg of GHK-Cu plus 10 mg each of BPC-157 and TB-500. Total peptide content is 70 milligrams. Each component compound is also available standalone from Ronin Peptides. The blend format pairs them at convenient working concentrations for combined-compound benchwork. The three components engage three distinct receptor pathways. Researchers studying combined-compound research often choose the blend to simplify reconstitution. Ronin supplies the blend as a lyophilized vial. Reconstitution uses bacteriostatic water at the bench. Sale is limited to laboratory research. Human and veterinary use are excluded.
Why a blend rather than individual compounds?
Researchers studying combined-compound protocols often investigate the three blend components together. The three compounds engage distinct molecular pathways. They do not compete at the receptor or signalling-pathway level. The blend format provides convenient working concentrations at fixed ratios. It removes the need to reconstitute three separate vials and combine them at the bench. Researchers preferring independent concentration control can use the standalone single-compound vials for each component instead. Both formats deliver the same chemical entities; only the convenience differs.
What are the per-component concentrations after reconstitution?
A single 70 mg vial reconstituted with 2 mL of bacteriostatic water yields GHK-Cu at 25 mg/mL, BPC-157 at 5 mg/mL, and TB-500 at 5 mg/mL simultaneously. Other diluent volumes scale linearly. The three peptides share the same diluent volume but contribute distinct working concentrations corresponding to their per-vial loadings (50 mg, 10 mg, 10 mg respectively). Researchers should choose the reconstitution volume based on which component's working concentration is the primary experimental anchor.
What is the regulatory status of Glow Blend?
No regulatory body has approved any of the three component compounds as a drug for human or veterinary use. The list spans Health Canada, the FDA, the EMA, the TGA, and any equivalent. The blend formulation has not been approved either. GHK-Cu carries cosmetic-ingredient approval under the INCI name Copper Tripeptide-1 in multiple jurisdictions. Cosmetic ingredient approval is regulatorily distinct from drug approval. It applies to the GHK-Cu component only.
None of the three compounds are listed as scheduled controlled substances. The blend is also not scheduled. The international drug-control conventions and major national scheduling systems do not cover any of the components. The blend sits within the regulatory layer covering laboratory reagents and research chemicals. It is not in the layer governing human therapeutics. It is not in the layer governing cosmetic finished products.
Ronin Peptides supplies the blend as a research-grade reagent for bench-research applications. Buyers operate under their own jurisdictional laws when handling the compound. Researchers must apply any institutional review protocols at their own discretion. Ronin Peptides assumes no oversight of downstream lab practice.
How is Glow Blend verified?
Each batch passes through Janoshik Analytical — an independent peptide-analytics lab — for HPLC purity quantification of each of the three component compounds and MS identity confirmation of each component, with the minimum acceptance threshold set at 99 percent purity per component by HPLC. Every Janoshik COA includes a verification key that resolves at janoshik.com, plus per-component analytical results showing the three distinct compounds. To pull the COA covering the batch on your order, email support@roninpeptides.ca from the address used at checkout, with your order number; the typical reply turnaround is well under 24 hours.
Why is the Glow Blend powder blue?
The blue tint comes from the GHK-Cu component specifically. The Cu(II) chromophore — the copper-2 ion bound at the histidine-imidazole chelation pocket of the GHK tripeptide — absorbs visible light in the orange-red wavelength range and transmits the complementary blue. The BPC-157 and TB-500 components do not contribute to the colour. Loss of the blue tint during storage signals dissociation of the GHK-Cu Cu(II) complex specifically, but does not directly indicate the status of the BPC-157 or TB-500 components, which require COA mass-spec data for status confirmation.
How is Glow Blend reconstituted?
The standard preparation is 2 mL of bacteriostatic water added to a 70 mg vial, producing a solution with GHK-Cu at 25 mg/mL, BPC-157 at 5 mg/mL, and TB-500 at 5 mg/mL. Inject the water against the inside wall of the vial — never directly onto the lyophilized powder, which causes foaming and surface denaturation. Swirl gently or invert slowly until fully dissolved (typically 30–60 seconds). The reconstituted solution should appear transparent with a blue tint. Refrigerate at 2–8 °C immediately after reconstitution. Use the Ronin reconstitution calculator for non-standard volumes or to convert per-component target doses to insulin-syringe units.
How do I receive the COA for my batch?
Email support@roninpeptides.ca from the email address used at checkout, with your order number (e.g., RP-CA-1234) and the compound name. We reply within 24 hours — typically the same business day — with the COA PDF attached. The COA includes the Janoshik verification key and per-component analytical results for the three blend components, which you can check independently at janoshik.com to confirm the test results match what the laboratory ran on your specific batch. COAs are not published publicly to protect supply-chain privacy and prevent competitor scraping.
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PMID: 27847966 | doi:10.1007/s00109-016-1488-y
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID: 21030672 | doi:10.1152/japplphysiol.00945.2010
- Seiwerth S et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID: 34267654 | doi:10.3389/fphar.2021.627533
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology. 2024;32(5):3119-3161. PMID: 38980576 | doi:10.1007/s10787-024-01499-8
- Conato C et al. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour. Biochim Biophys Acta. 2001;1526(2):199-210. PMID: 11325542 | doi:10.1016/s0304-4165(01)00127-1
- Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730 | doi:10.1155/2015/648108
- Pickart L et al. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520 | doi:10.3390/ijms19071987
- Bian Y et al. The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis. Redox Biol. 2024;75:103237. PMID: 38879894 | doi:10.1016/j.redox.2024.103237
- Yarmola EG et al. Formation and implications of a ternary complex of profilin, thymosin beta 4, and actin. J Biol Chem. 2001;276(49):45555-45563. PMID: 11579089 | doi:10.1074/jbc.M105723200
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145 | doi:10.1038/nature03000
- Sosne G et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. PMID: 11950239 | doi:10.1006/exer.2001.1125
- Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-275. PMID: 27450738 | doi:10.1016/bs.vh.2016.04.005
- Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries. Sports Med. 2026. PMID: 41966639 | doi:10.1007/s40279-026-02437-0
- Rahman OF et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID: 41490200 | doi:10.5435/JAAOSGlobal-D-25-00236
